Palittapongarnpim P,Tantivitayakul P,Aiewsakun P,Mahasirimongkol S,Jaemsai B .2024 .Genomic Interactions Between Mycobacterium tuberculosis and Humans. Annual Review of Genomics and Human Genetics, 25 : .
Organization WH .2024 .Consolidated guidance on tuberculosis data generation and use. Module 1. , : .
Naeem A,Badshah SL,Muska M,Ahmad N,Khan K. .2016 .The current case of quinolones: synthetic approaches and antibacterial activity. Molecules, 21(4) : 268.
Singh S,Kaur G,Mangla V,Gupta MK .2015 .Quinoline and quinolones: promising scaffolds for future antimycobacterial agents. Journal of enzyme inhibition and medicinal chemistry, 30(3) : 492-504.
Fan Y-L,Wu J,Cheng X-W,Z X-W .2018 .Feng L-S. Fluoroquinolone derivatives and their anti-tubercular activities. European journal of medicinal chemistry, 146 : 554-63.
Organization WH .2019 .WHO consolidated guidelines on drug-resistant tuberculosis treatment. , : .
Castro RA,Ross A,Kamwela L,Reinhard M,Loiseau C,Feldmann J .2020 .The genetic background modulates the evolution of fluoroquinolone-resistance in Mycobacterium tuberculosis. Molecular biology and evolution, 37(1) : 195-207.
Kanji A,Hasan R .2019 .Efflux pump as alternate mechanism for drug resistance in Mycobacterium tuberculosis. Indian Journal of Tuberculosis, 66(1) : 20-5.
Rossolini GM,Arena F,Pecile P,Pollini S. .2014 .Update on the antibiotic resistance crisis. Current opinion in pharmacology., 18 : 56-60.
Wallis RS,Maeurer M,Mwaba P,Chakaya J,Rustomjee R,Migliori GB .2016 .Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. The Lancet infectious diseases, 16(4) : e34-e46.
Hoagland DT,Liu J,Lee RB,Lee RE .2016 .New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Advanced drug delivery reviews, 102 : 55-72.
Tiberi S,Du Plessis N,Walzl G,Vjecha MJ,Rao M,Ntoumi F .2018 .Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. The Lancet Infectious Diseases, 18(7) : e183-e98.
Qin X,Jiang B,Song H,Du N,Zhang Y,Zhong X .2023 .Design, synthesis and anti-TB and anti-bacterial activity of Ciprofloxacin derivatives containing N-(amino) piperazine moieties. Medicinal Chemistry Research, 32(3) : 556-70.
Szulczyk D,Woziński M,Koliński M,Kmiecik S,Głogowska A,Augustynowicz-Kopeć E .2023 .Menthol-and thymol-based ciprofloxacin derivatives against Mycobacterium tuberculosis: In vitro activity, lipophilicity, and computational studies. Scientific Reports, 13(1) : 16328.
Skepper CK,Armstrong D,Balibar CJ,Bauer D,Bellamacina C,Benton BM .2020 .Topoisomerase inhibitors addressing fluoroquinolone resistance in Gram-negative bacteria. Journal of Medicinal Chemistry, 63(14) : 7773-816.
Fallica AN,Barbaraci C,Amata E,Pasquinucci L,Turnaturi R,Dichiara M .2021 .Nitric oxide photo-donor hybrids of ciprofloxacin and norfloxacin: a shift in activity from antimicrobial to anticancer agents. Journal of Medicinal Chemistry, 64(15) : 11597-613.
Halder SK,Elma F. .2021 .In silico identification of novel chemical compounds with antituberculosis activity for the inhibition of InhA and EthR proteins from Mycobacterium tuberculosis. J Clin Tuberc Other Mycobact Dis, 24 : 100246.
Sonnenkalb L,Carter JJ,Spitaleri A,Iqbal Z,Hunt M,Malone KM .2023 .Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Lancet Microbe, 4(5) : e358-e68.
Krisnamurti GC .2021 .Capsaicinoids from Capsicum annuum as an Alternative FabH Inhibitor of Mycobacterium Tuberculosis: In Silico Study. Makara Journal of Science, 25(4) : .
Valencia J,Rubio V,Puerto G,Vasquez L,Bernal A,Mora JR .2022 .Biological Evaluation of Novel Quinolinone-Based Thiosemicarbazones against Mycobacterium tuberculosis. Antibiotics, 12(1) : 61.
Coba-Males MA,Santamaría-Aguirre J,Alcívar-León CD .2021 .In Silico Evaluation of New Fluoroquinolones as Possible Inhibitors of Bacterial Gyrases in Resistant Gram-Negative Pathogens. , 43 : .
Coba-Males MA,Lavecchia MJ,Alcivar-Leon CD,Santamaria-Aguirre J. Novel CD .2023 .Fluoroquinolones with Possible Antibacterial Activity in Gram-Negative Resistant Pathogens: In Silico Drug Discovery. Molecules, 28(19) : .
Mahwish Akhtar AI,Sabahat Abdullah,Imran Mohammad .2025 .Computational Studies on Analogues of 8-Methoxy Derivatives of Fluoroquinolones as Potential Inhibitors of Mycobacterium Tuberculosis. RADS J Pharm Allied Health Sci, 3(1) : 25-49.
Benselama W,Benchouk W. .2024 .In silico design based on quantum chemical, molecular docking studies and ADMET predictions of ciprofloxacin derivatives as novel potential antibacterial and antimycrobacterium agents. J Biomol Struct Dyn, 42(15) : 7650-66.
Szulczyk D,Wozinski M,Kolinski M,Kmiecik S,Glogowska A,Augustynowicz-Kopec E .2023 .Menthol- and thymol-based ciprofloxacin derivatives against Mycobacterium tuberculosis: in vitro activity, lipophilicity, and computational studies. Sci Rep, 13(1) : 16328.
Studio BD .2020 .. , : .
Blower TR,Williamson BH,Kerns RJ,Berger JM .2016 .Crystal structure and stability of gyrasefluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences, 113(7) : 1706-13.
Daina A,Michielin O,Zoete V. .2017 .SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports, 7(1) : 42717.
Pires DE,Blundell TL,Ascher DB .2015 .pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of medicinal chemistry, 58(9) : 4066-72.
Xiong G,Wu Z,Yi J,Fu L,Yang Z,Hsieh C .2021 .0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic acids research, 49(W1) : W5-W14.
Veber DF,Johnson SR,Cheng H,Smith BR,Ward KW,Kopple KD .2002 .Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry, 45(12) : 2615-23.
Lipinski CA,Lombardo F,Dominy BW,Feeney PJ .1997 .Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 23(1-3) : 3-25.
Ghose AK,Viswanadhan VN,Wendoloski JJ .1999 .A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of combinatorial chemistry, 1(1) : 55-68.
Egan WJ,Merz KM,Baldwin JJ KM .2000 .Prediction of drug absorption using multivariate statistics. Journal of medicinal chemistry, 43(21) : 3867-77.
Muegge I,Heald SL,Brittelli D. .2001 .Simple selection criteria for drug-like chemical matter. Journal of medicinal chemistry, 44(12) : 1841-6.
Paixão P,Gouveia LF,Morais JA LF .2009 .Prediction of drug distribution within blood. european journal of pharmaceutical sciences, 36(4-5) : 544-54.
Norinder U,Haeberlein M. .2002 .Computational approaches to the prediction of the bloodbrain distribution. Advanced drug delivery reviews, 54(3) : 291-313.
Rendic S,Guengerich FP .2015 .Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. , 28(1) : 38-42.